IP Library Granted Patent US 9,271,953
Granted Patent B2
US 9,271,953 · App. 14/209,717 · Granted Mar 1, 2016

Methods for correction of organ dysfunction

Inventor: Diana Driscoll (Roanoke, TX)
Assignee: GENETIC DISEASE INVESTIGATORS, LLC
A61K31/221A61K31/14A61K31/465A61K31/4748A61K31/51A61K31/685A61K33/06A61K45/06A61K9/0014A61K9/0031A61K9/0034A61K31/205
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,271,953
App. No.
14/209,717
Granted
Mar 1, 2016
Kind
B2
Abstract

The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases.

Claims (19)

1. A method of treating autonomic dysfunctions in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a choline compound; a cholinesterase inhibitor and Acetyl-L-Carnitine in an amount effective to treat one or more of the following autonomic dysfunctions associated with collagen disorders: Ehlers-Danlos syndrome, Marfan's syndrome, Loeys-Dietz syndrome, Stickler syndrome, fibrillary disorders, elastin disorders, or Joint Hypermobility Syndrome.

2. The method of claim 1 , wherein the composition treats or prevents symptoms associated with autonomic disorders including constipation, gastroparesis, idiopathic gastrointestinal dysmotility, low gastric acid production, ileocecal valve dysfunction (“ileus”), breathing difficulties, low gall bladder ejection fractions, biliary dyskinesia, acalculous gall bladder disease, Sphincter of Oddi dysfunction, low cholecystokinin (“CCK”) production, poor kidney function, non-alcoholic steatohepatitis (or “NASH”), or non-alcoholic fatty liver disease.

3. The method of claim 1 , wherein the composition comprises:

a choline compound selected from at least one of choline at 100 mg to 1,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;

75 mcg to 300 mcg of a cholinesterase inhibitor is huperzine A; and

50 mg to 600 mg of Acetyl-L-Carnitine.

4. The method of claim 1 , wherein the composition further comprises Thiamin.

5. The method of claim 1 , wherein the composition further comprises Magnesium.

6. The method of claim 1 , wherein the composition comprises per dose:

a choline compound selected from at least one of choline at 100 mg to 3,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;

75 mcg of huperzine A;

150 mg of Acetyl-L-Carnitine; and

optionally 30 mg Thiamin and 30 mg Magnesium.

7. The method of claim 1 , wherein the range per dose is 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 270, 300, 350, 400, 450, 500, 540, 600, 700, 750, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 30 to 2,400, 40 to 2,300, 50 to 2,000, 60 to 1,500, 70 to 1,000, 80 to 750, 90 to 2,400, 200 to 2,300, 300 to 2,200, 400 to 2,100, 500 to 2,000, 600 to 1,900, 700 to 1,800, 800 to 1,700, 900 to 1,600, 1,000 to 1,500, 1,100 to 1,400, 1,200 to 1,300 mg, of the choline compound.

8. The method of claim 1 , wherein the range per dose is 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 75 to 300, 80 to 275, 90 to 250, 100 to 225, 125 to 200, 150 to 175 micrograms of huperzine A.

9. The method of claim 1 , wherein the range per dose is 50, 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 50 to 600, 75 to 600, 80 to 575, 90 to 550, 100 to 525, 125 to 500, 150 to 475, 175 to 450, 200 to 425, 225 to 400, 250 to 375, 275 to 350, 300 to 325 mg Acetyl-L-Carnitine.

10. The method of claim 4 , wherein the range per dose is 10, 20, 30, 40, 50, 60 mg Thiamin.

11. The method of claim 5 , wherein the range per dose is 0.3, 0.5, 0.75, 1.0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 mg Magnesium.

12. The method of claim 1 , wherein the composition is adapted to be administered prenatally, orally, intravenously, intraperitoneally, intranasally, intrapulmonary, subcutaneously, intracutaneously, or intramuscularly.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2014
From: DRISCOLL, DIANA
To: GENETIC DISEASE INVESTIGATORS, LLC
Reel/Frame 033080/0389 →
Continuity (4)
Provisional Application 61779131 · Mar 13, 2013
Provisional Application 61856938 · Jul 22, 2013
Provisional Application 61900697 · Nov 6, 2013
Related Publication 20140274957A1 · Sep 18, 2014